The best Bull and Bear pitches based on recency and number of recommendations.
Even more than the lousy bets I did make in 2011, I regret failing to realize the potential of hepatitis C polymerase inhibitors to turn perennially weak companies like Inhibitex and Idenix into explosive winners. I did profit well from Anadys, but I… More
Definitely not feeling the Tulipmania buzz in the hepatitis C sector. Couldn't stand the premium that Gilead ponied up for Pharmasset and see even less of a chance of that happening to Inhibitex. Not even out of phase 2 clinical trials, yet a market… More
Read the most recent pitches from players about INHX.DL.
Find the members with the highest scoring picks in INHX.DL.
See what the Wall Street professionals think, according to their public statements and filings.